Abstract

Objective:

The estimation of disease severity based on early biomarkers may facilitate treatment and reduce mortality in patients with COVID-19. The present retrospective, observational study evaluates the role of different inflammatory indices in predicting mortality in COVID-19 patients.

Materials and Methods:

The prognostic value for the prediction of 30-day mortality of inflammatory parameters [C-reactive protein (CRP), ferritin, procalcitonin (PCT)] and [neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), derived NLR (dNLR), systemic inflammation index (SII), C-reactive protein-to-lymphocyte ratio (CRP/L), C-reactive protein-to-albumin ratio, and neutrophi-lto-lymphocyte and platelet ratio (N/LP)] were evaluated upon the initial admission of 305 COVID-19 patients to the intensive care unit.

Results:

In this study, APACHE score, ferritin, PCT and CRP/L were significantly higher in the non-survivors than in survivors. No significant differences were found in the other inflammatory indices. High ferritin (p<0.001) and high APACHE scores (p<0.001) were identified as predictors of in-hospital mortality in a ROC curve analysis. Only a high ferritin level was identified as an independent risk factor for mortality in a multivariate regression analysis (p=0.002).

Conclusion:

Inflammatory indices were not identified as predictors of mortality in critically ill COVID-19 patients admitted to the intensive care unit in the present study; and only high ferritin levels among the parameters related to inflammation were identified as an independent risk factor for mortality.

Keywords: COVID-19, biomarker, inflammatory indices, ferritin, mortality

References

  1. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574-81.
  2. van Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, et al. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. J Pathol. 2021;254:307-31.
  3. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504.
  4. Doganci S, Ince ME, Ors N, Yildirim AK, Sir E, Karabacak K, et al. A new COVID-19 prediction scoring model for in-hospital mortality: experiences from Turkey, single center retrospective cohort analysis. Eur Rev Med Pharmacol Sci. 2020;24:10247-57.
  5. Usul E, Şan İ, Bekgöz B, Şahin A. Role of hematological parameters in COVID-19 patients in the emergency room. Biomark Med. 2020;14:1207-15.
  6. 6.Tomar B, Anders HJ, Desai J, Mulay SR. Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19. Cells. 2020;9:1383.
  7. Karimi A, Shobeiri P, Kulasinghe A, Rezaei N. Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis. Front Immunol. 2021;12:741061.
  8. Fois AG, Paliogiannis P, Scano V, Cau S, Babudieri S, Perra R, et al. The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients. Molecules. 2020;25:5725.
  9. Rokni M, Ahmadikia K, Asghari S, Mashaei S, Hassanali F. Comparison of clinical, para-clinical and laboratory findings in survived and deceased patients with COVID-19: diagnostic role of inflammatory indications in determining the severity of illness. BMC Infect Dis. 2020;20:869.
  10. Tjendra Y, Al Mana AF, Espejo AP, Akgun Y, Millan NC, Gomez-Fernandez C, et al. Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers. Arch Pathol Lab Med. 2020;144:1465-74.
  11. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13.
  12. Paliogiannis P, Zinellu A, Scano V, Mulas G, De Riu G, Pascale RM, et al. Laboratory test alterations in patients with COVID-19 and non COVID-19 interstitial pneumonia: a preliminary report. J Infect Dev Ctries. 2020;14:685-90.
  13. Gerotziafas GT, Sergentanis TN, Voiriot G, Lassel L, Papageorgiou C, Elabbadi A, et al. Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. Thromb Haemost. 2020;120:1680-90.
  14. Vanderschueren S, Deeren D, Knockaert DC, Bobbaers H, Bossuyt X, Peetermans W. Extremely elevated C-reactive protein. Eur J Intern Med. 2006;17:430-3.
  15. Vasileva D, Badawi A. C-reactive protein as a biomarker of severe H1N1 influenza. Inflamm Res. 2019;68:39-46.
  16. Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019. Clin Infect Dis. 2020;71:2174-9.
  17. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42:2270-9.
  18. Yang M, Chen X, Xu Y. A Retrospective Study of the C-Reactive Protein to Lymphocyte Ratio and Disease Severity in 108 Patients with Early COVID-19 Pneumonia from January to March 2020 in Wuhan, China. Med Sci Monit. 2020;26:e926393.
  19. Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S, et al. Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19. J Clin Med Res. 2020;12:415-22.
  20. Acar E, Demir A, Yıldırım B, Kaya MG, Gökçek K. The role of hemogram parameters and C-reactive protein in predicting mortality in COVID-19 infection. Int J Clin Pract. 2021;75:e14256.
  21. Tonduangu N, Le Borgne P, Lefebvre F, Alame K, Bérard L, Gottwalles Y, et al. Prognostic Value of C-Reactive Protein to Lymphocyte Ratio (CLR) in Emergency Department Patients with SARS-CoV-2 Infection. J Pers Med. 2021;11:1274.
  22. Lucijanic M, Demaria M, Gnjidic J, Rob Z, Filipovic D, Penovic T, Jordan A, Barisic-Jaman M, Pastrović F, Lucijanic D, Cikara T, Lucijanic T, Miletic M, Ljubicic D, Keres T. Higher ferritin levels in COVID-19 patients are associated with hyperinflammation, worse prognosis, and more bacterial infections without pronounced features of hemophagocytosis. Ann Hematol. 2022 May;101(5):1119-1121.
  23. Hou H, Zhang B, Huang H, Luo Y, Wu S, Tang G, et al. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. Clin Exp Immunol. 2020;201:76-84.
  24. Cecconi M, Piovani D, Brunetta E, Aghemo A, Greco M, Ciccarelli M, et al. Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. J Clin Med. 2020;9:1548.
  25. Para O, Caruso L, Pestelli G, Tangianu F, Carrara D, Maddaluni L, et al. Ferritin as prognostic marker in COVID-19: the FerVid study. Postgrad Med. 2022;134:58-63.
  26. Cleland DA, Eranki AP Procalcitonin. StatPearls; [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. [cited: 2020 Apr 22]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK539794/
  27. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57:389-99.
  28. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190-1.
  29. Kotula JJ, Moore WS, Chopra A, Cies JJ. Association of Procalcitonin Value and Bacterial Coinfections in Pediatric Patients With Viral Lower Respiratory Tract Infections Admitted to the Pediatric Intensive Care Unit. J Pediatr Pharmacol Ther. 2018;23:466-72.
  30. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75:1730-41.
  31. Ding X, Yu Y, Lu B, Huo J, Chen M, Kang Y. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019. Clin Chem Lab Med. 2020;58:1365-71.
  32. Seyit M, Avci E, Nar R, Senol H, Yilmaz A, Ozen M, et al. Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19. Am J Emerg Med. 2021;40:110-4.
  33. Xue G, Gan X, Wu Z, Xie D, Xiong Y, Hua L, et al. Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19. Int Immunopharmacol. 2020;89:107065.
  34. Kudlinski B, Zgoła D, Stolińska M, Murkos M, Kania J, Nowak P, et al. Systemic Inflammatory Predictors of In-Hospital Mortality in COVID-19 Patients: A Retrospective Study. Diagnostics. 2022;12:859.
  35. COVID-19 Rehberi [İnternet]. T.C. Sağlık Bakanlığı COVID-19 Bilgilendirme Platformu. [erişim tarihi: 7 Kasım 2020]. Erişim adresi: https://covid19.saglik.gov.tr/TR-66341/antisitokin-antiinflamatuar-tedaviler-koagulopati-yonetimi.html

Copyright and license

Copyright © 2024 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite?

1.
Demirel A, Miniksar ÖH. The Role of Inflammatory Indices in Predicting Intensive Care Unit Mortality in Critically Ill COVID-19 Patients. Turk J Intensive Care. 2024;22(4):239-247. https://doi.org/10.4274/tybd.galenos.2023.82621